Description: Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Home Page: www.allergytherapeutics.com
Dominion Way
Worthing,
BN14 8SA
United Kingdom
Phone:
44 1903 844 700
Officers
| Name | Title |
|---|---|
| Mr. Manuel Llobet | CEO & Executive Director |
| Dr. Shaun Antony Furlong | CFO & Executive Director |
| Dr. Murray Skinner | Chief Scientific Officer |
| Ms. Sue Baker | Head of Human Resources |
| Simon Piggott | Head of Clinical Science |
| Alan Bullimore | Head of Communication & Market Development |
| Mr. Russell Picket | Group Financial Controller |
| Karley Charlotte Mouatt Cheesman | Company Secretary |
| Mr. Matthew Heath | Principal Scientist |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 68.2371 |
| Price-to-Sales TTM: | 6.1343 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |